Eledon Pharmaceuticals (ELDN) Non-Current Assets (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Non-Current Assets data on file, last reported at $33.1 million in Q1 2026.

• Quarterly Non-Current Assets fell 1.48% year-over-year to $33.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $133.5 million (changed 0.09% YoY) and the FY2025 annual result came in at $33.3 million, down 1.05% from the prior year.
• Non-Current Assets retreated to $33.1 million in Q1 2026, from $33.3 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $82.1 million in Q1 2022 to a low of $32.8 million in Q1 2024.
• A 5-year average of $41.9 million and a median of $33.3 million in 2025 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2023 — Non-Current Assets plunged 59.67% — and 2025, when it advanced 2.28%.
• Tracing ELDN's Non-Current Assets over 5 years: stood at $33.3 million in 2022, then decreased by 1.02% to $32.9 million in 2023, then advanced by 2.24% to $33.7 million in 2024, then retreated by 1.05% to $33.3 million in 2025, then retreated by 0.68% to $33.1 million in 2026.
• The last three Non-Current Assets figures came in at $33.1 million (Q1 2026), $33.3 million (Q4 2025), and $33.6 million (Q3 2025), per Business Quant data.